Background and Objectives: Chronic thromboembolic pulmonary hypertension (CTEPH) is a chronic progressive disease, resulting from persistent arterial obstruction combined with small-vessel remodeling. Central and peripheral CTEPH are distinguished, according to the dominant lesion's location. This is important for surgical or percutaneous interventional assessment or for medical treatment. Material and Methods: Eighty-one patients (51 male/30 female) with confirmed CTEPH were analyzed, while the CENTRAL type included 51 patients (63%) and the PERIPHERAL type 30 patients (37%). Results: A significant difference in CENTRAL type vs. PERIPHERAL type was determined in gender (male 72.5% vs. 46.7%; p = 0.0198). No difference was found in age, functional status, or echocardiographic parameters. Invasive hemodynamic parameters showed a significant difference in mean pulmonary arterial pressure (46 vs. 58 mmHg; p = 0.0002), transpulmonary gradient (34 vs. 47 mmHg; p = 0.0005), and cardiac index (2.04 vs. 2.5 L.min.m2; p = 0.02) but not in pulmonary vascular resistance. Risk factors showed a significant difference only in acute pulmonary embolism (93.8% vs. 60%; p = 0.0002) and malignancy (2% vs. 13.3%; p = 0.0426). Conclusions: Our study showed hemodynamic differences between CENTRAL type vs. PERIPHERAL type CTEPH with a worse hemodynamic picture in CENTRAL form. This may indicate a different pathophysiological response and/or possible additional influences contributing especially to the peripheral pulmonary bed affection.

2nd Department of Surgery Department of Cardiovascular Surgery 1st Faculty of Medicine General University Hospital Charles University U nemocnice 2 128 02 Prague Czech Republic

Center for Pulmonary Hypertension 1st Faculty of Medicine General University Hospital Charles University U nemocnice 2 128 02 Prague Czech Republic

Department of Cardiology and Angiology CTEPH Expert Centre Medical Faculty The National Institute of Cardiovascular Diseases Slovak Medical University Pod Krasnou horkou 1 833 48 Bratislava Slovakia

Zobrazit více v PubMed

Galiè N., Humbert M., Vachiery J., Gibbs S., Lang I., Torbicki A., Simmonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur. Heart J. 2016;37:67–119. doi: 10.1093/eurheartj/ehv317. PubMed DOI

Delcroix M., Torbicki A., Gopalan D., Sitbon O., Klok F.A., Lang I., Jenkins D., Kim N.H., Humbert M., Jais X., et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2020;57:2002828. doi: 10.1183/13993003.02828-2020. PubMed DOI

Kim N.H., Delcroix M., Jais X., Madani M.M., Matsubara H., Mayer E., Ogo T., Tapson V.F., Ghofrani H.-A., Jenkins D.P. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2019;53:1801915. doi: 10.1183/13993003.01915-2018. PubMed DOI PMC

Lang I.M., Campean I.A., Sadushi-Kolici R., Badr-Eslam R., Gerges C., Skoro-Sajer N. Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension. Clin. Chest Med. 2021;42:81–90. doi: 10.1016/j.ccm.2020.11.014. PubMed DOI

Šimková I. Pulmonary Hypertension by the Eye of a Cardiologist. Slovak Academic Press; Bratislava, Slovakia: 2009. CTEPH: Patophysiology, clinical picture, diagnosis; pp. 199–215.

Lang I. Chronic thromboembolic pulmonary hypertension: A distinct disease entity. Eur. Respir. Rev. 2015;24:246–252. doi: 10.1183/16000617.00001115. PubMed DOI PMC

Simonneau G., Torbicki A., Dorfmüller P., Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 2017;26:160112. doi: 10.1183/16000617.0112-2016. PubMed DOI PMC

Simonneau G., Dorfmüller P., Guignabert C., Mercier O., Humbert M. Chronic thromboembolic pulmonary hypertension: The magic of pathophysiology. Ann. Cardiothorac. Surg. 2022;11:106–119. doi: 10.21037/acs-2021-pte-10. PubMed DOI PMC

Lang I.M., Pesavento R., Bonderman D., Yuan J.X.-J. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: A current understanding. Eur. Respir. J. 2012;41:462–468. doi: 10.1183/09031936.00049312. PubMed DOI

Delcroix M., Kerr K., Fedullo P. Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk Factors. Ann. Am. Thorac. Soc. 2016;13:S201–S206. doi: 10.1513/AnnalsATS.201509-621AS. PubMed DOI

Jansa P., Ambrož D., Kuhn M., Dytrych V., Aschermann M., Černý V., Gressin V., Heller S., Kunstýř J., Širanec M., et al. Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic. Pulm. Circ. 2022;12:e12038. doi: 10.1002/pul2.12038. PubMed DOI PMC

Ciurzyński M., Kurzyna M., Kopeć G., Błaszczak P., Chrzanowski Ł., Kamiński K., Mizia-Stec K., Mularek-Kubzdela T., Biederman A., Zieliński D., et al. An expert opinion of the Polish Cardiac Society Working Group on Pulmonary Circulation on screening for chronic thromboembolic pulmonary hypertension patients after acute pulmonary embolism: Update. Kardiol. Polska. 2022;80:723–732. doi: 10.33963/KP.a2022.0141. PubMed DOI

E Cannon J., Jenkins D.P., Hoole S.P. Chronic thromboembolic pulmonary hypertension: A review of risk factors, management and current challenges. Expert Rev. Cardiovasc. Ther. 2022;20:35–43. doi: 10.1080/14779072.2022.2034499. PubMed DOI

Dorfmüller P., Günther S., Ghigna M.-R., De Montpréville V.T., Boulate D., Paul J.-F., Jais X., Decante B., Simonneau G., Dartevelle P., et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: A role for pulmonary veins and systemic vasculature. Eur. Respir. J. 2014;44:1275–1288. doi: 10.1183/09031936.00169113. PubMed DOI

Quarck R., Wynants M., Verbeken E., Meyns B., Delcroix M. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2015;46:431–443. doi: 10.1183/09031936.00009914. PubMed DOI

Remková A., Šimková I., Valkovičová T. Platelet abnormalities in chronic thromboembolic pulmonary hypertension. Int. J. Clin. Exp. Med. 2015;8:9700–9707. PubMed PMC

Colebank M.J., Qureshi M.U., Rajagopal S., Krasuski R.A., Olufsen M.S. A multiscale model of vascular function in chronic thromboembolic pulmonary hypertension. Am. J. Physiol. Circ. Physiol. 2021;321:H318–H338. doi: 10.1152/ajpheart.00086.2021. PubMed DOI PMC

D’Armini A.M. Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 2015;24:253–262. doi: 10.1183/16000617.00000915. PubMed DOI PMC

Delcroix M., Lang I., Pepke-Zaba J., Jansa P., D’Armini A.M., Snijder R., Bresser P., Torbicki A., Mellemkjaer S., Lewczuk J., et al. Long-Term Outcome of Patients with Chronic Thromboembolic Pulmonary Hypertension:Results From an International Prospective Registry. Circulation. 2016;133:859–871. doi: 10.1161/CIRCULATIONAHA.115.016522. PubMed DOI

Kopeć G., Dzikowska-Diduch O., Mroczek E., Mularek-Kubzdela T., Chrzanowski Ł., Skoczylas I., Tomaszewski M., Peregud-Pogorzelska M., Karasek D., Lewicka E., et al. Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: Data from the Polish multicenter registry (BNP-PL) Ther. Adv. Chronic. Dis. 2021;12:204062232110029. doi: 10.1177/20406223211002961. PubMed DOI PMC

Ruaro B., Confalonieri P., Caforio G., Baratella E., Pozzan R., Tavano S., Bozzi C., Lerda S., Geri P., Biolo M., et al. Chronic Thromboembolic Pulmonary Hypertension: An Observational Study. Medicina. 2022;58:1094. doi: 10.3390/medicina58081094. PubMed DOI PMC

Mahmud E., Madani M.M., Kim N.H., Poch D., Ang L., Behnamfar O., Patel M.P., Auger W.R. Chronic Thromboembolic Pulmonary Hypertension. J. Am. Coll. Cardiol. 2018;71:2468–2486. doi: 10.1016/j.jacc.2018.04.009. PubMed DOI

Verbelen T., Godinas L., Maleux G., Coolen J., Claessen G., Belge C., Meyns B., Delcroix M. Chronic thromboembolic pulmonary hypertension: Diagnosis, operability assessment and patient selection for pulmonary endarterectomy. Ann. Cardiothorac. Surg. 2021;11:82–97. doi: 10.21037/acs-2021-pte-12. PubMed DOI PMC

Lindner J., Ambroz D., Novotný R., Nižňanský M., Simkova I., Boháčeková M., Pecha O., Jansa P. Pulmonary endarterectomy combined with cardiac surgery: A 7-year retrospective analysis. Cor. Vasa. 2015;57:e115–e120. doi: 10.1016/j.crvasa.2015.02.009. DOI

Jenkins D. Pulmonary endarterectomy: The potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 2015;24:263–271. doi: 10.1183/16000617.00000815. PubMed DOI PMC

Skoro-Sajer N., Marta G., Gerges C., Hlavin G., Nierlich P., Taghavi S., Sadushi-Kolici R., Klepetko W., Lang I.M. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax. 2013;69:116–122. doi: 10.1136/thoraxjnl-2013-203746. PubMed DOI PMC

Lang I., Meyer B.C., Ogo T., Matsubara H., Kurzyna M., Ghofrani H.-A., Mayer E., Brenot P. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 2017;26:160119. doi: 10.1183/16000617.0119-2016. PubMed DOI PMC

Coghlan J.G., Rothman A.M., Hoole S.P. Balloon Pulmonary Angioplasty: State of the Art. Interv. Cardiol. Rev. Res. Resour. 2021;16:e02. doi: 10.15420/icr.2020.14. PubMed DOI PMC

Gerges C., Friewald R., Gerges M., Shafran I., Sadushi-Koliçi R., Skoro-Sajer N., Moser B., Taghavi S., Klepetko W., Lang I.M. Efficacy and Safety of Percutaneous Pulmonary Artery Subtotal Occlusion and Chronic Total Occlusion Intervention in Chronic Thromboembolic Pulmonary Hypertension. Circ. Cardiovasc. Interv. 2021;14:e010243. doi: 10.1161/CIRCINTERVENTIONS.120.010243. PubMed DOI

Butler O., Ju S., Hoernig S., Vogtländer K., Bansilal S., Heresi G.A. Assessment for residual disease after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. ERJ Open Res. 2022;8:00572–02021. doi: 10.1183/23120541.00572-2021. PubMed DOI PMC

Ghofrani H.-A., D’Armini A.M., Grimminger F., Hoeper M.M., Jansa P., Kim N.H., Mayer E., Simonneau G., Wilkins M.R., Fritsch A., et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N. Engl. J. Med. 2013;369:319–329. doi: 10.1056/NEJMoa1209657. PubMed DOI

Hoeper M.M. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 2015;24:272–282. doi: 10.1183/16000617.00001015. PubMed DOI PMC

Sadushi-Kolici R., Jansa P., Kopeć G., Torbicki A., Skoro-Sajer N., Campean I.-A., Halank M., Simkova I., Karlocai K., Steringer-Mascherbauer R., et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): A double-blind, phase 3, randomised controlled trial. Lancet Respir. Med. 2018;7:239–248. doi: 10.1016/S2213-2600(18)30367-9. PubMed DOI

Ghofrani H.-A., D’Armini A.M., Kim N.H., Mayer E., Simonneau G. Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. Respir. Med. 2021;177:106293. doi: 10.1016/j.rmed.2020.106293. PubMed DOI

Pepke-Zaba J., Delcroix M., Lang I., Mayer E., Jansa P., Ambroz D., Treacy C., Monforte A.D., Morsolini M., Snijder R., et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Results from an international prospective registry. Circulation. 2011;124:1973–1981. doi: 10.1161/CIRCULATIONAHA.110.015008. PubMed DOI

Nakamura M., Okada O., Sakuma M., Nakanishi N., Miyahara Y., Yamada N., Fujioka H., Kuriyama T., Kunieda T., Sugimoto T., et al. Incidence and Clinical Characteristics of Chronic Pulmonary Thromboembolism in Japan Compared with Acute Pulmonary Thromboembolism. Circ. J. 2002;66:257–260. doi: 10.1253/circj.66.257. PubMed DOI

Chausheva S., Naito A., Ogawa A., Seidl V., Winter M.-P., Sharma S., Sadushi-Kolici R., Campean I.-A., Taghavi S., Moser B., et al. Chronic thromboembolic pulmonary hypertension in Austria and Japan. J. Thorac. Cardiovasc. Surg. 2019;158:604–614. doi: 10.1016/j.jtcvs.2019.01.019. PubMed DOI

Bohacekova M., Kaldararova M., Valkovicova T., Remkova A., Vesely J., Simkova I. Risk factors detection in chronic thromboembolic pulmonary hypertension, a tool for risk quantification? Bratisl. Med. J. 2017;117:577–582. doi: 10.4149/BLL_2016_112. PubMed DOI

Gerges C., Skoro-Sajer N., Lang I.M. Right Ventricle in Acute and Chronic Pulmonary Embolism (2013 Grover Conference Series) Pulm. Circ. 2014;4:378–386. doi: 10.1086/676748. PubMed DOI PMC

Tello K., Dalmer A., Axmann J., Vanderpool R., Ghofrani H.A., Naeije R., Roller F., Seeger W., Sommer N., Wilhelm J., et al. Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload. Circ. Heart Fail. 2019;12:e005512. doi: 10.1161/CIRCHEARTFAILURE.118.005512. PubMed DOI

Greyson C.R. Pathophysiology of right ventricular failure. Crit. Care Med. 2008;36:S57–S65. doi: 10.1097/01.CCM.0000296265.52518.70. PubMed DOI

Hopkins W.E. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron. Artery Dis. 2005;16:19–25. doi: 10.1097/00019501-200502000-00004. PubMed DOI

Valkovicova T., Kaldararova M., Reptova A., Bohacekova M., Bacharova L., Hatala R., Simkova I. Eisenmenger syndrome —An electrocardiographic and echocardiographic assessment of the right ventricle. Bratisl. Med. J. 2018;119:321–329. doi: 10.4149/BLL_2018_060. PubMed DOI

Diller G.-P., Dimopoulos K., Kafka H., Ho S.Y., Gatzoulis M.A. Model of chronic adaptation: Right ventricular function in Eisenmenger syndrome. Eur. Heart J. Suppl. 2007;9:H54–H60. doi: 10.1093/eurheartj/sum019. DOI